Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer

NCT00977860 is registered in ClinicalTrials.gov with Adam Olson as lead sponsor.

NCT NCT00977860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00977860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer
Lead sponsor
Adam Olson
Phase
Not applicable
Overall status
Completed
Start date
October 7, 2010
Completion date
July 8, 2022
Enrollment
163 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer